The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based ... both have a long duration of action, allowing once-daily administration.

Moreover, the inhibition of DPP-4 activity may contribute to enhanced GLP-1 action, which is consistent with the lowered postprandial circulating levels of TG, cholesterol-rich TRL-apoB48 ...

GLP-1 RAs and SGLT2 inhibitors significantly reduce cardiovascular events and heart failure risk in older adults with type 2 diabetes compared to DPP-4 inhibitors. The study utilized health ...

agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss ...

Next, they tested the platform for delivering GLP-1 receptor agonists in a mouse model for type 2 diabetes and metabolic-induced obesity. Pentelute and his colleagues found that the mice ...

The first cohort included 36,082 GLP-1 receptor agonist users (dulaglutide [Trulicity], exenatide, liraglutide [Victoza], ...

Both DPP-4 inhibitors and GLP ... actions," the researchers continued. "The anti-inflammatory effects of these drugs, alongside improvements in glycemic control and systemic changes in metabolism ...

After taking into account age, sex, socioeconomic status, diabetes severity, and a history of mental ill health, the use of GLP-1 receptor agonists was not associated with an increased risk of ...

rising at a CAGR of 6.3% The market is categorized by drug type into GLP-1 receptor agonists and DPP-4 inhibitors, with a market size of USD 35.5 billion in 2023. The rising demand for GLP-1 ...